You Position: Home > Paper
CYP4F2 polymorphism as a genetic risk factor for major hemorrhagic complications in Chinese patients on warfarin therapy
( views:97, downloads:8 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF GERIATRIC CARDIOLOGY
- Issue:
- 2
- DOI:
- 10.3724/SP.J.1263.2012.04162
- Key Word:
- CYP4F2;Genetic risk factor;Warfarin;Complications
Abstract： @@ To the editor Warfarin is a commonly used anticoagulant with a narrow therapeutic range and risk of hemorrhagic complications.[1] After CYP2C9 and VKORC1, CYP4F2 was confirmed as the third principle genetic determinant of warfarin dose variability.[2,3] CYP4F2 functions as a vitamin K1 (VK1) oxidase, a counterpart to vitamin K oxidize reductase (encoded by VKORC1) in limiting excessive accumulation of VK1 in vitamin K cycle.[4]
- [1]King CR,Burmester JK,Turpaz Y,etc.CYP4F2 genetic variant alters required warfarin dose.[J].2008,111(8).
- [2]Fihn, Stephan D.,McDonell, Mary,Martin, Donald,etc.Risk Factors for Complications of Chronic Anticoagulation.[J].1993,118(7).
- [3]McDonald MG,Nakano M,Rieder MJ.CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.[J].2009,75(6).
- [4]Higashi MitchellK,Wittkowsky AnnK,Veenstra DavidL,etc.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.[J].2002,287(13).
- [5]G P, Aithal,C P, Day,P J, Kesteven,etc.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.[J].1999,353.
- [6]Wadelius M,Chen LY,Lindh JD,etc.The largest prospective warfarin-treated cohort supports genetic forecasting.[J].2009,113(4).
- [7]Kim RB,Ritchie MD,Dudek SM,etc.Genetic determinants of response to warfarin during initial anticoagulation.[J].2008,358(10).
- [8]Adler BK,Acton RT,McGwin G,etc.Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.[J].2008,83(2).
- [9]Lundgren S,Rane A,Lindh JD,etc.Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.[J].2005,78(5).